TCI Wealth Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

TCI Wealth Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-240	Closed	-$1.56K	–	1961
2023 Q1	$1.56K	Buy	+240	New	+$1.84K	﹤0.01%	2021
2021 Q3	–	Sell	-92	Closed	-$3K	–	2561
2021 Q2	$3K	Buy	+92	New	+$2.95K	﹤0.01%	1855

Other funds holding SPRY

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCI Wealth Advisors's SPRY Position: Q2 2023 in Review

TCI Wealth Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 240 shares — an estimated $1.56K sold.

TCI Wealth Advisors first reported a position in SPRY in Q2 2021 and held it in 2 quarters. The position peaked at $3K in Q2 2021. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

TCI Wealth Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 240 ARS Pharmaceuticals shares in Q2 2023, an estimated $1.56K.
TCI Wealth Advisors first reported a position in ARS Pharmaceuticals in Q2 2021 and held it in 2 quarters.
TCI Wealth Advisors's ARS Pharmaceuticals position peaked at $3K in Q2 2021.
92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.